MMED:CC News and Press, MIND MEDICINE INC.

Hallucinogenic persistent perception disorder (HPPD) is an intoxication disorder caused by psychedelic drugs that encompasses a range of visual disturbances that occur in different time frames. The disorder also causes extreme anxiety as well as out-of-body sensations and is marked by shame as w...

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present posters describing the...

All Common shares will remain listed on Nasdaq Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today ...

New research suggests that hallucinogenic mushrooms that contain psilocybin may be useful in the treatment of conditions such as anxiety, post-traumatic stress disorder and obsessive-compulsive disorders. Professor Bernard Lerer, the author of the study, stated that researchers were interested ...

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management...

Research has shown that psychedelics may be useful in the treatment of a range of mental-health conditions, including anxiety, depression and post-traumatic stress disorder. Now, Okanagan researchers are looking into whether psychedelics can help manage alcoholism. Okanagan Clinical Trials is...

Mind Medicine (MindMed) Inc . (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing of an underwritten offering of 1...

-A single oral administration of MM120 100 µg met its key secondary endpoint and maintained a clinically and statistically significant HAM-A reductions compared to placebo at 12 weeks with a 65% clinical response rate and 48% clinical remission rate- -MindMed plans to hold an End-of-...

- Data update includes 12-week topline Phase 2b results for MM120 in Generalized Anxiety Disorder (GAD) - - Results from Phase 1 pharmacokinetics bridging trial for MM120 oral dissolving tablet (ODT) formulation to be discussed - Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), ...

--Announced statistically significant and clinically meaningful topline Phase 2b data for MM120 at 4 weeks in Generalized Anxiety Disorder (GAD)-- --Multiple planned milestones for MM120 in GAD, including 12-week Phase 2b data to be presented at March 7th investor event, and initiation of...